NOVO NORDISK A/S
Last · XETRA€40.00-0.35 (-0.87%)stale · yahoo · 98h ago
Market cap€176.8B3.35B sh
P/E · TTM11.4fwd — · eps 3.51
Beta0.34vs S&P 500
Div yield3.91%annual · TTM
52w range
€30.23€54.87
Volume99.8Ksession
| Revenue | DKK 309.1B |
|---|---|
| Operating income | DKK 127.7B |
| Net income | DKK 102.4B |
| Free cash flow | DKK 59.0B |
| Operating margin | 41.3% |
| Net margin | 33.1% |
| Return on equity | 52.8% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2026-04-07
- Current Ratio Low
Red flags
- Current Ratio Low — Current ratio 0.80
Upcoming earnings
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
—
Est. revenue
72.8B
Press & signals
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
- Satelight
Can weight-loss drugs lose their nasty side effects?
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags